Trial
NCT05102162
BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Florida
Collaborators
Food and Drug Administration (FDA)
Condition
Pneumonia
Intervention
Cefepime, Meropenem, or Piperacillin/Tazobactam
Why stopped
Low recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-12